Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial.

In patients who were cured with avelumab or resistant to avelumab, baseline FIGO scores were similar (median 5 [range, 3-14] v 5 [range, 4-8], respectively), whereas there was a nonsignificant trend for a lower proportion of patients with metastatic (stage III) disease among those cured by avelumab (37.5%) versus those with resistance (57.1%).

also in 5,406 other papers